Literature DB >> 27107430

Cryoglobulinaemic vasculitis at diagnosis predicts mortality in primary Sjögren syndrome: analysis of 515 patients.

Soledad Retamozo1, Hoda Gheitasi1, Luca Quartuccio2, Belchin Kostov3, Laura Corazza2, Albert Bové1, Antoni Sisó-Almirall4, Myriam Gandía1, Manuel Ramos-Casals5, Salvatore De Vita2, Pilar Brito-Zerón1.   

Abstract

OBJECTIVE: To evaluate the fulfilment of classification criteria for cryoglobulinaemic vasculitis (CV) at diagnosis in a large cohort of patients with primary SS and their correlation with poor outcomes.
METHODS: We included 515 consecutive patients tested for serum cryoglobulins who fulfilled the 2002 classification criteria for primary SS. CV classification criteria and serum cryoglobulins at diagnosis were assessed as predictors of death and lymphoma using Cox proportional-hazards regression analysis adjusted for age and gender.
RESULTS: Positive serum cryoglobulins were detected in 65 (12%) patients, of whom 21 (32%) fulfilled CV classification criteria. Compared with patients positive for cryoglobulins who did not fulfil CV criteria, patients with CV had a higher frequency of type II cryoglobulinaemia (86% vs 43%, P = 0.04), a higher mean cryocrit level (6.58% vs 1.25%, P < 0.001) and a higher cumulated mean EULAR-SS disease activity index score (35.3 vs 16.2, P < 0.001). After a mean follow-up of 110 months, 45 (9%) patients developed B-cell lymphoma and 33 (6%) died. Compared with patients without cryoglobulins, patients with cryoglobulins who fulfilled [hazard ratio (HR) = 7.47, 95% CI: 3.38, 16.53] and did not fulfil (HR = 2.56, 95% CI: 1.03, 6.35) CV criteria both showed a higher risk of B-cell lymphoma in the univariate analysis, but not in the multivariate models. Compared with patients without cryoglobulins, patients with CV had a higher risk of death in both the univariate (HR = 11.68, 95% CI: 4.44, 30.74) and multivariate (HR = 4.36, 95% CI: 1.32, 14.47) models.
CONCLUSION: Patients with primary SS who fulfilled criteria for cryoglobulinaemic vasculitis at diagnosis are at higher risk of death.
© The Author 2016. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  ESSDAI; Sjögren syndrome; cryoglobulinaemia; mortality; vasculitis

Mesh:

Year:  2016        PMID: 27107430     DOI: 10.1093/rheumatology/kew194

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  12 in total

Review 1.  Cutaneous and Mucosal Manifestations of Sjögren's Syndrome.

Authors:  Elena Generali; Antonio Costanzo; Carlo Mainetti; Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2017-12       Impact factor: 8.667

2.  A patient presenting with isolated hematuria and renal dysfunction as rare manifestation of cryoglobulinemic glomerulonephritis in the course of autoimmune diseases including Sjögren's syndrome.

Authors:  Masaki Yamanaka; Yoshihide Fujigaki; Hajime Kono; Michito Nagura; Shigeyuki Arai; Yoshifuru Tamura; Tatsuru Ota; Shigeru Shibata; Fukuo Kondo; Yutaka Yamaguchi; Shunya Uchida
Journal:  CEN Case Rep       Date:  2018-04-18

3.  Incidence and Mortality of Physician-Diagnosed Primary Sjögren Syndrome: Time Trends Over a 40-Year Period in a Population-Based US Cohort.

Authors:  Gabriel Maciel; Cynthia S Crowson; Eric L Matteson; Divi Cornec
Journal:  Mayo Clin Proc       Date:  2017-05       Impact factor: 7.616

4.  Prognostic value of Sjögren's syndrome autoantibodies.

Authors:  R Hal Scofield; Anum Fayyaz; Biji T Kurien; Kristi A Koelsch
Journal:  J Lab Precis Med       Date:  2018-10-30

5.  Predictable biomarkers of developing lymphoma in patients with Sjögren syndrome: a nationwide population-based cohort study.

Authors:  Yu-Hsiang Chiu; Chi-Hsiang Chung; Kuen-Tze Lin; Chin-Sheng Lin; Jia-Hong Chen; Hsiang-Cheng Chen; Ren-Yeong Huang; Chi-Tsung Wu; Feng-Cheng Liu; Wu-Chien Chien
Journal:  Oncotarget       Date:  2017-07-25

6.  Characterization and risk estimate of cancer in patients with primary Sjögren syndrome.

Authors:  Pilar Brito-Zerón; Belchin Kostov; Guadalupe Fraile; Daniel Caravia-Durán; Brenda Maure; Francisco-Javier Rascón; Mónica Zamora; Arnau Casanovas; Miguel Lopez-Dupla; Mar Ripoll; Blanca Pinilla; Eva Fonseca; Miriam Akasbi; Gloria de la Red; Miguel-Angel Duarte-Millán; Patricia Fanlo; Pablo Guisado-Vasco; Roberto Pérez-Alvarez; Antonio J Chamorro; César Morcillo; Iratxe Jiménez-Heredia; Isabel Sánchez-Berná; Armando López-Guillermo; Manuel Ramos-Casals
Journal:  J Hematol Oncol       Date:  2017-04-17       Impact factor: 17.388

Review 7.  Lymphoma and Lymphomagenesis in Primary Sjögren's Syndrome.

Authors:  Alessia Alunno; Maria Comasia Leone; Roberto Giacomelli; Roberto Gerli; Francesco Carubbi
Journal:  Front Med (Lausanne)       Date:  2018-04-13

8.  Articular and Peripheral Nervous System Involvement Are Linked to the Long-Term Outcome in Primary Sjögren's Syndrome: The Relevance of Single Organ Manifestations Rather Than a Composite Score as Predictors.

Authors:  Luca Quartuccio; Saviana Gandolfo; Alen Zabotti; Sara Zandonella Callegher; Cinzia Fabro; Salvatore De Vita
Journal:  Front Immunol       Date:  2019-07-10       Impact factor: 7.561

9.  Survival Analysis of Turkish Patients With Systemic Lupus Erythematosus: Older Age at Diagnosis Affects Mortality.

Authors:  Döndü Üsküdar Cansu; Hava Üsküdar Teke; Cengiz Korkmaz
Journal:  Arch Rheumatol       Date:  2017-03-21       Impact factor: 1.472

Review 10.  Hepatitis B Virus-Related Cryoglobulinemic Vasculitis: Review of the Literature and Long-Term Follow-Up Analysis of 18 Patients Treated with Nucleos(t)ide Analogues from the Italian Study Group of Cryoglobulinemia (GISC).

Authors:  Cesare Mazzaro; Luigino Dal Maso; Laura Gragnani; Marcella Visentini; Francesco Saccardo; Davide Filippini; Pietro Andreone; Anna Linda Zignego; Valter Gattei; Giuseppe Monti; Massimo Galli; Luca Quartuccio
Journal:  Viruses       Date:  2021-05-30       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.